m6A modification on the fate of colorectal cancer: functions and mechanisms of cell proliferation and tumorigenesis

Jiang, Xiaohan; Jin, Ziyao; Yang, Yuan; Zheng, Xiang; Chen, Shaohua; Wang, Shuaijie; Zhang, Xuemei; Qu, Nanfang

doi:10.3389/fonc.2023.1162300

Cited by 9 publications

(5 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dynamic, reversible alteration of RNA m6A is essential for the development and spread of tumours. Oncogene and tumour suppressor gene m6A alteration research may provide fresh approaches to the detection and therapy of cancer 22 . The m6A alteration sites of NDE1 were examined via the SRAMP portal.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive analysis indicated that NDE1 is a potential biomarker for pan‐cancer and promotes bladder cancer progression

Wang,

Ning,

Chen

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe nuclear distribution E homologue 1 (NDE1) is a crucial dynein binding partner. The NDE1 protein has the potential to disrupt the normal functioning of centrosomes, leading to a compromised ability to generate spindles and ensure precise separation of chromosomes during cell division. The potential consequences of this phenomenon include genomic instability, malignant transformation and the proliferation of neoplastic growths. However, studies examining the connection between NDE1 and cancer is still very rare.MethodsThe expression level, prognostic impact, gene change, DNA methylation, protein interaction, mRNA m6A modification, ceRNA network, associated gene and function enrichment, and immune‐related effects of NDE1 in pan‐cancer were examined using a range of online analytic tools and the R software package. The CCK‐8 test, transwell assay, scratch assay and colony formation assay were used to confirm the effects of NDE1 on the proliferation, invasion and metastasis of bladder cancer cells.ResultsNumerous tumour types have elevated NDE1, which is linked to a bad prognosis. NDE1 is an excellent diagnostic tool for many different types of cancer. Numerous malignancies have been linked to genetic changes in NDE1. NDE1 was connected to TMB, MSI, several immunological checkpoint genes and immune cell infiltration. NDE1 is linked to a number of immunological subtypes. NDE1 could affect how well immunotherapy works to treat different types of cancer. NDE1 was mostly associated with cell cycle, chromosomal segregation, DNA replication and mitotic segregation, according to GO and KEGG analyses. NDE1 physically binds to PAFAH1B1 and DCTN1, respectively. The proliferation, invasion and metastasis of bladder cancer cells may be prevented by NDE1 knockdown. Furthermore, knockdown of NDE1 promoted the apoptosis of bladder cancer cells.ConclusionHigh expression of NDE1 is present in a variety of tumours, which is linked to a bad prognosis for cancer. Knockdown of NDE1 inhibited the proliferation, invasion and metastasis of bladder cancer cells, and promoted the apoptosis. For a number of malignancies, NDE1 may be a biomarker for immunotherapy and prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Oncogene and tumour suppressor gene m6A alteration research may provide fresh approaches to the detection and therapy of cancer. 22 The m6A alteration sites of NDE1 were examined via the SRAMP portal. There is a very strong probability that m6A may modify 15 of NDE1's functional regions.…”

Section: Resultsmentioning

confidence: 99%

Comprehensive analysis indicated that NDE1 is a potential biomarker for pan‐cancer and promotes bladder cancer progression

Wang,

Ning,

Chen

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…These clues may be employed independently of other biomarkers to forecast the prognosis of CRC ( Lu et al, 2021 ). There is no denying that m 6 A modification is fundamental to CRC formation and advancement ( Jiang et al, 2023 ). On top of that, the mutual interaction mechanism between circRNAs and lncRNAs make them promising biomarkers in CRC.…”

Section: Biomarkers Of Ncrnas and M 6 A Regulators...mentioning

confidence: 99%

New understandings of the genetic regulatory relationship between non-coding RNAs and m6A modification

Liu,

Xiang

2023

Front. Genet.

View full text Add to dashboard Cite

One of the most frequent epigenetic modifications of RNA in eukaryotes is N6 methyladenosine (m6A), which is mostly present in messenger RNAs. Through the influence of several RNA processing stages, m6A modification is a crucial approach for controlling gene expression, especially in cancer progression. It is universally acknowledged that numerous non-coding RNAs (ncRNAs), such as microRNAs, circular RNAs, long non-coding RNAs, and piRNAs, are also significantly affected by m6A modification, and the complex genetic regulatory relationship between m6A and ncRNAs plays a pivotal role in the development of cancer. The connection between m6A modifications and ncRNAs offers an opportunity to explore the oncogene potential regulatory mechanisms and suggests that m6A modifications and ncRNAs could be vital biomarkers for multiple cancers. In this review, we discuss the mechanisms of interaction between m6A methylation and ncRNAs in cancer, and we also summarize diagnostic and prognostic biomarkers for clinical cancer detection. Furthermore, our article includes some methodologies for identifying m6A sites when assessing biomarker potential.

show abstract

“…Therefore, the ability to identify prognostic risk factors of cancer types and understand their growth, progression, and treatments has been highly valued by researchers. Although genetic, genomic, and biochemical approaches have unveiled numerous molecular mechanisms that contribute to tumorigenesis, recent developments have shown that N 6 -methyladenosine (m 6 A) RNA modification is closely associated with both activation and inhibition of tumorigenesis ( Du et al, 2022 ; Ma et al, 2022 ; Zhang et al, 2022 ; Jiang et al, 2023 ). m 6 A RNA modification involves the attachment of a methyl group to the 6-carbon of adenosine, constituting a cotranscriptional and dynamically regulated mark catalyzed by a series of enzymes ( Leonetti et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Expression patterns of m6A RNA methylation regulators under apoptotic conditions in various human cancer cell lines

ALASAR,

SAĞLAM,

VATANSEVER

et al. 2024

Turkish Journal of Biology

View full text Add to dashboard Cite

Background/aim Cancer is a complex disease that involves both genetic and epigenetic factors. While emerging evidence clearly suggests that changes in epitranscriptomics play a crucial role in cancer pathogenesis, a comprehensive understanding of the writers, erasers, and readers of epitranscriptomic processes, particularly under apoptotic conditions remains lacking. The aim of this study was to uncover the changes in the expression of m 6 A RNA modifiers under apoptotic conditions across various cancer cell lines. Materials and methods Initially, we quantified the abundance of m 6 A RNA modifiers in cervical (HeLa and ME180), breast (MCF7 and MDA-MB-231), lung (A549 and H1299), and colon (Caco-2 and HCT116) cancer cell lines using qPCR. Subsequently, we induced apoptosis using cisplatin and tumor necrosis factor-alpha (TNF-α) to activate intrinsic and extrinsic pathways, respectively, and assessed apoptosis rates via flow cytometry. Further, we examined the transcript abundance of m 6 A RNA modifiers under apoptotic conditions in cervical, breast, and lung cancer cell lines using qPCR. Results Overall, treatment with cisplatin increased the abundance of m 6 A modifiers, whereas TNF-α treatment decreased their expression in cervical, breast, and lung cancer cell lines. Specifically, cisplatin-induced apoptosis, but not TNF-α-mediated apoptosis, resulted in decreased abundance of METTL14 and FTO transcripts. Additionally, cisplatin treatment drastically reduced the abundance of IGF2BP2 and IGF2BP3 readers. Conclusion These results suggest that the differential response of cancer cells to apoptotic inducers may be partially attributed to the expression of m 6 A RNA modifiers.

show abstract

m6A modification on the fate of colorectal cancer: functions and mechanisms of cell proliferation and tumorigenesis

Cited by 9 publications

References 115 publications

Comprehensive analysis indicated that NDE1 is a potential biomarker for pan‐cancer and promotes bladder cancer progression

Comprehensive analysis indicated that NDE1 is a potential biomarker for pan‐cancer and promotes bladder cancer progression

New understandings of the genetic regulatory relationship between non-coding RNAs and m6A modification

Expression patterns of m6A RNA methylation regulators under apoptotic conditions in various human cancer cell lines

Contact Info

Product

Resources

About